2016 Fiscal Year Final Research Report
Molecular mechanisms of development of Down syndrome-associated acute lymphoblastic leukemia and novel therapeutic targets for this disease
| Project/Area Number |
26461560
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Pediatrics
|
|---|
| Research Institution | Hirosaki University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Keywords | ダウン症候群 / 急性リンパ性白血病 / レセプターチロシンキナーゼ / RAS / CRLF2 / JAK / 分子標的治療 / エピゲノム |
|---|
| Outline of Final Research Achievements |
We performed this study to clarify molecular mechanisms of development of Down syndrome-associated acute lymphoblastic leukemia (DS-ALL)and to find novel therapeutic targets, and obtained the following results.
1. Gene alterations in the receptor tyrosine kinase (RTK)-RAS and the CRLF2-JAK pathways were found in about 40% and 20% of Japanese DS-ALL patients, respectively, and they were mutually exclusive. It is suggested that these pathways are potential therapeutic targets.
2. Gene mutations in epigenetic regurators were found in about half of Japanese DS-ALL patients lacking both RTK-RAS and CRLF2-JAK pathway mutations. Epigenetic agents may be useful for these patients.
|
| Free Research Field |
小児科学
|
